DBV Technologies DBVT 深 滬
等待開盤 10-29 09:30:00 美东时间
10.65
+0.525
+5.19%
華盛通- 最 高10.86
- 今 開10.06
- 成交量 22.58万股
- 最 低 10.03
- 昨 收 10.125
- 總市值 6.69亿
- 52周最高 26.185
- 市盈率 靜 --
- 換手率 0.36%
- 52周最低 8.63
- 委 比 -85.27%
- 總股本 6284.85万
- 歷史最高 505.70
- 量 比 0.43
- 振 幅 8.20%
- 歷史最低 2.2045
- 每 手 1
- 風險率 3.88%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多DBV Technologies Q3 2026 Earnings Call Transcript
DBV Technologies (NASDAQ:DBVT) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzin...
今天 05:47
DBV Technologies Q3 EPS $(0.14) Beats $(0.24) Estimate, Sales $1.600M Beat $820.000K Estimate
DBV Technologies (NASDAQ:DBVT) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.24) by 41.67 percent. This is a 41.67 percent increase over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $1.600 millio...
今天 04:53
DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026
DBV Technologies will release its third quarter 2026 financial results and business update on October 28, 2026, at 5:00 p.m. ET, with a live conference call and webcast available to investors. The company, focused on developing treatments for food allergies using its VIASKIN® patch technology, is headquartered in France and listed on Euronext and Nasdaq. Interested parties can join via the provided phone numbers or the webcast link on the company...
10-27 20:30
DBV Technologies收涨1.48%，成交额1372.16万美元
10月22日，DBV Technologies（DBVT）收涨1.48%，报9.62美元，成交额1372.16万美元，市值6.05亿美元。 行情数据 • 开盘价...
10-22 06:03
DBV Technologies收跌0.66%，成交额526.53万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:05
Reported Earlier, DBV Technologies Submits BLA To FDA For VIASKIN Peanut Patch In Children Aged 4-7 With Peanut Allergy, Requests Priority Review
DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years The BLA is supported by the results from the successful Phase 3 VITESSE trial – the largest immunotherapy clinical trial to date for this population. DBV has r...
09-30 15:43
DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years
DBV Technologies has submitted a Biologics License Application (BLA) to the U.S. FDA for the VIASKIN® Peanut Patch for children aged 4-7 with peanut allergy. The BLA is supported by positive results from the VITESSE Phase 3 trial, the largest immunotherapy trial for this population. DBV has requested Priority Review for the application. The VIASKIN® Patch uses epicutaneous immunotherapy to deliver allergen protein through the skin, aiming to dese...
09-29 22:29
DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq
DBV Technologies announced the sale of approximately $50 million of ADSs through its At-The-Market (ATM) Program on Nasdaq. The ADSs, representing new ordinary shares, were sold to RA Capital Management, L.P. at a price of $13.67 per ADS, reflecting a 0.15% discount to the closing price on Euronext Paris. The issuance will dilute existing shareholders by approximately 5.82% and the new shares will represent 6.18% of the existing shares on Euronex...
07-30 21:40
DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales
DBV Technologies filed a new shelf registration statement with the SEC for an at-the-market (ATM) offering of up to $150 million in American Depositary Shares (ADS). Each ADS represents five ordinary shares. The ATM Program, established under a 2025 sales agreement with Citizens JMP Securities, allows the company to sell ADSs to qualified investors, with proceeds to be used for manufacturing expansion, clinical trials for peanut allergy treatment...
07-17 21:00
